Loading...

CHRS COHERUS ONCOLOGY INC Company Mergers 8-K Filing

CHRS

CHRS

COHERUS ONCOLOGY INC

(CHRS)

2026 8-K

Financial Results Update

Financial Results Report

Stock Offering Announcement

Clinical Supply Agreement

Stock Offering Announcement

Financial Update

Financial Results Update

Compliance Regained

Financial Statements

Notice of Delisting

Financial Statements

Management Change

Financial Results

Director Resignation

Financial Results

Supply Chain Update

Financial Results and Appoi...

Agreement with Apotex

Asset Purchase Agreement

Appointment of Rita A. Kara...

Annual Meeting of Stockholders

Earnings Reports

Loan Facility and Revenue P...

Earnings Reports

Divestiture of Assets

Appointment of Georgia Erbe...

Loan Agreement Amendment

Divestment Agreement

Termination of TIGIT Progra...

Appointment of Interim CFO

Departure of Directors

FDA Approval and Pricing An...

Merger of Equals

Financial Results

Merger of Equals

FDA Approval and Payment of...

Lease Extension

Capital Structure Changes

Earnings Reports

Merger Agreement

Litigation/Dispute

Annual Meeting Results

FDA Inspection Completed

Underwriting Agreement

Amendment to Sales Agreement

Earnings Report

Financial Results and Workf...

External Links:

On February 4, 2026, Coherus Oncology announced a deal with Janssen to evaluate their monoclonal antibody, tagmokitug, in a Phase 1b study for prostate cancer, with Janssen supplying a bispecific antibody, pasritamig.

AI Assistant

COHERUS ONCOLOGY INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.